Salsalate
Salsalate is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| salsalate | unapproved drug other | 2023-05-16 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| arthritis | EFO_0005856 | D001168 | M05-M14 |
| fever | HP_0001945 | D005334 | R50.9 |
| pain | EFO_0003843 | D010146 | R52 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
34 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | 3 | 3 | 1 | — | 5 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | — | 1 | 1 | 2 |
| Alcoholic fatty liver | D005235 | K70.0 | — | — | — | 1 | — | 1 | |
| Psychotic disorders | D011618 | F20.81 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Insulin resistance | D007333 | EFO_0002614 | 2 | 3 | 1 | — | 2 | 6 | |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | 2 | 2 | — | — | 2 |
| Inflammation | D007249 | — | 2 | 1 | — | — | 2 | ||
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 2 | 1 | — | — | 2 |
| Peripheral nervous system diseases | D010523 | G64 | — | 2 | 1 | — | — | 2 | |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 1 | 1 | — | — | 1 |
| Coronary artery disease | D003324 | I25.1 | — | 1 | 1 | — | — | 1 | |
| Overweight | D050177 | E66.3 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myelodysplastic syndromes | D009190 | D46 | 1 | 1 | — | — | — | 2 | |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | 1 | 1 | — | — | — | 2 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | 1 | — | — | — | 2 |
| Myeloid leukemia acute | D015470 | C92.0 | — | 1 | — | — | — | 1 | |
| Myelomonocytic leukemia chronic | D015477 | C93.1 | — | 1 | — | — | — | 1 | |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | — | 1 | — | — | — | 1 |
| Vascular stiffness | D059289 | — | 1 | — | — | — | 1 | ||
| Anemia | D000740 | EFO_0004272 | D64.9 | — | 1 | — | — | — | 1 |
| Hiv | D006678 | O98.7 | — | 1 | — | — | — | 1 | |
| Diabetic neuropathies | D003929 | EFO_1000783 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pre-eclampsia | D011225 | EFO_0000668 | O14 | 1 | — | — | — | — | 1 |
| Hyperglycemia | D006943 | HP_0003074 | R73.9 | 1 | — | — | — | — | 1 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | — | — | — | — | 1 |
| Progressive supranuclear palsy | D013494 | EFO_0002512 | G23.1 | 1 | — | — | — | — | 1 |
| Leukemia | D007938 | C95 | 1 | — | — | — | — | 1 | |
| Endometriosis | D004715 | EFO_0001065 | N80 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 1 | 1 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | SALSALATE |
| INN | salsalate |
| Description | Salsalate is a dimeric benzoate ester obtained by intermolecular condensation between the carboxy of one molecule of salicylic acid with the phenol group of a second. It is a prodrug for salycylic acid that is used for treatment of rheumatoid arthritis and osteoarthritis and also shows activity against type II diabetes. It has a role as a non-steroidal anti-inflammatory drug, a non-narcotic analgesic, an antirheumatic drug, a hypoglycemic agent, an antineoplastic agent, an EC 3.5.2.6 (beta-lactamase) inhibitor and a prodrug. It is a benzoate ester, a member of benzoic acids, a member of phenols and a member of salicylates. It is functionally related to a salicylic acid. |
| Classification | Small molecule |
| Drug class | anti-inflammatory agents (salicylic acid derivatives); anti-inflammatory agents (salicylic acid derivatives) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=C(Oc1ccccc1C(=O)O)c1ccccc1O |
Identifiers
| PDB | — |
| CAS-ID | 552-94-3 |
| RxCUI | 36108 |
| ChEMBL ID | CHEMBL154111 |
| ChEBI ID | 9014 |
| PubChem CID | 5161 |
| DrugBank | DB01399 |
| UNII ID | V9MO595C9I (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 993 documents
View more details
Safety
Black-box Warning
Black-box warning for: Salsalate
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
160 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more